| Identification | Back Directory | [Name]
AHAS inhibitor | [CAS]
219793-45-0 | [Synonyms]
CS-1880
BTB06584
AHAS inhibitor
BTB06584 >=98% (HPLC)
AHAS inhibitor BTB06584
AHAS inhibitor USP/EP/BP
BTB 06584;BTB-06584;BTB06584
AHAS inhibitor
LM-3254
03-11 cq
-Chlorobenzoic acid 2-nitro-5-(phenylsulfonyl)phenyl ester
4-Chlorobenzoic acid 2-nitro-5-(phenylsulfonyl)phenyl ester
Benzoic acid, 4-chloro-, 2-nitro-5-(phenylsulfonyl)phenyl ester
4-Chlorobenzoic acid 2-nitro-5-(phenylsulfonyl)phenyl ester AHAS inhibitor BTB06584
AHAS inhibitor 4-Chlorobenzoic acid 2-nitro-5-(phenylsulfonyl)phenyl ester | [Molecular Formula]
C19H12ClNO6S | [MDL Number]
MFCD00103060 | [MOL File]
219793-45-0.mol | [Molecular Weight]
417.82 |
| Chemical Properties | Back Directory | [Boiling point ]
664.8±55.0 °C(Predicted) | [density ]
1.466±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20° C | [solubility ]
<2.47 mg/mL in EtOH insoluble in; ≥17.05 mg/mL in DMSO; insoluble in H2O | [form ]
solid | [color ]
White to off-white | [InChI]
1S/C19H12ClNO6S/c20-14-8-6-13(7-9-14)19(22)27-18-12-16(10-11-17(18)21(23)24)28(25,26)15-4-2-1-3-5-15/h1-12H | [InChIKey]
WNDWKKPBLAKXMI-UHFFFAOYSA-N | [SMILES]
O=S(C1=CC=C([N+]([O-])=O)C(OC(C2=CC=C(Cl)C=C2)=O)=C1)(C3=CC=CC=C3)=O |
| Hazard Information | Back Directory | [Uses]
BTB06584 is F1 Fo-ATPase inhibitor. It can be used in biological study of novel acetohydroxyacid synthase inhibitors as active agents against Mycobacterium tuberculosis. | [Biological Activity]
ischaemia compromises mitochondrial respiration. consequently, the mitochondrial 1fo-atp synthase reverses and plays as a proton-pumping atpase, so maintaining the mitochondrial membrane potential (δψm), while accelerating atp depletion and cell death. btb06584 is an if1-dependent selective inhibitor of the mitochondrial f1fo-atpase. | [in vitro]
btb inhibited f1fo-atpase activity with no effect on the mitochondrial membrane potential (δψm) or o2 consumption. atp consumption decreased via inhibition of respiration, and ischaemic cell death was reduced. btb efficiency increased by if1 overexpression and reduced by silencing this protein. in addition, btb rescued defective haemoglobin synthesis in zebrafish pinotage (pnt) mutants in which expression of the atpif1a gene is lost [1]. | [Enzyme inhibitor]
This (FW = 417.82 g/mol; CAS 219793-45-0; Solubility: 84 mg/mL DMSO;
< 1 mg/mL HO), also named 2-nitro-5- (phenylsulfonyl) phenyl 4-
2
chlorobenzoate, inhibits F1Fo-ATPase activity, with no effect on
mitochondrial membrane potential (ΔΨm) or O2 consumption. ATP
consumption was significantly slowed after inhibition of respiration, and
ischemic cell death was reduced. BTB efficiency was increased by IF1
overexpression, and reduced by silencing the protein. | [in vivo]
the btb-mediated protection was further tested in neurons. primary cultured cortical neurons of mice were exposed to ogd, treated or not with btb, followed by rx. the resulting cell death was significantly reduced by btb, as scored by pi staining, compared with cells left untreated during ogd [1]. | [References]
[1] ivanes f, faccenda d, gatliff j, ahmed aa, cocco s, cheng ch, allan e, russell c, duchen mr, campanella m. the compound btb06584 is an if1-dependent selective inhibitor of the mitochondrial f1 fo-atpase. br j pharmacol. 2014;171(18):4193-206. |
|
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|